Search
Close this search box.
Search
Close this search box.

Tag: South Africa

Boulder Imaging Powers First CDI2-Compliant Technology for Central Banks

LOUISVILLE, Colo., Feb. 12, 2025 (GLOBE NEWSWIRE) — Boulder Imaging, a leader in machine vision and artificial intelligence solutions, is proud to announce the world’s first Common Detector Interface 2 (CDI2)-compliant software. This pioneering software, combined with Authentix GemVision™ sensors and image processing and fitness algorithms, is designed to deliver

Duck Creek Technologies s’associe à Worldpay en vue d’améliorer les solutions de paiement

Ce partenariat stratégique offre des capacités de paiement internationales et évolutives à destination des compagnies d’assurance BOSTON, 11 févr. 2025 (GLOBE NEWSWIRE) — Duck Creek Technologies, le fournisseur mondial de solutions intelligentes qui dessine les futurs contours du secteur de l’assurance générale et IARD (incendies, accidents et risques divers) a

Italian Operator EOLO Selects Mavenir 5G SA Core for Europe’s First 5G Standalone mmWave FWA Network 

Mavenir’s cloud-native, flexible and agile 5G SA Core solution enables EOLO to cost-effectively deliver FWA broadband services to hard-to-connect areas across Italy RICHARDSON, Texas, Feb. 11, 2025 (GLOBE NEWSWIRE) — Mavenir, the cloud-native network infrastructure provider building the future of networks, has been selected by innovative telecommunications operator EOLO, Italy’s

Duck Creek Technologies Partners with Worldpay to Enhance Payments Solutions

Strategic partnership delivers future-proof, global payments capabilities for insurance carriers BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) — Duck Creek Technologies, the global intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, today announced a strategic partnership with Worldpay®, a global industry leader in payments technology

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end